Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

MedReleaf’s genetic test will help physicians prescribe cannabis with greater confidence

MedReleaf’s genetic test will help physicians prescribe cannabis with greater confidenceMarkham, Ontario-based Canadian cannabis producer MedReleaf (TSX: LEAF) announced it will introduce to physicians a patent-pending genetic testing product called ReleafDxTM to help them prescribe cannabis with greater accuracy for each patient. MedReleaf will partner with DynaCare to make this service available to physicians across Canada.

Medical cannabis usage is growing quickly in Canada. There were approximately 75,000 Canadians registered to purchase medical cannabis from a licensed producer in June 2016. That grew to over 200,000 a year later. However, the physician community is looking for more scientific evidence from which to base prescriptions, including strain and dose recommendations.

ReleafDxTM analyzes a patient’s DNA and health conditions to help physicians answer what dosage should be prescribed; and what cannabis product might work best for each person. Specifically, it analyzes biomarkers within metabolic pathways to help identify patients might metabolize cannabis more slowly or quickly than normal. This information will help minimize the chance of adverse reactions and maximize the likelihood of positive effects.

Dynacare, a LabCorp company, will manage the sample analysis and results reporting.  They offer the largest menu of diagnostic tests in Canada and is one of Canada’s largest certified genetic testing laboratories. The test is conducted with a cheek swab in the doctors’ office or at one of over 200 Dynacare Laboratory and Health Services Centers across Canada.

The stock rose p 4.39% on the news to US$12.87. It is up 90% in the last 6 months.

Source: MedReleaf

MedReleaf’s genetic test will help physicians prescribe cannabis with greater confidence

Cannin Investment Group: Your Hemp Stocks Experts is your trusted resource for hemp stocks. Our team of financial experts evaluates all emerging hemp stock investing opportunities. We aggregate hundreds of hours of market research to provide tips on the best hemp stocks for 2020. 

Use Cannin as your resource for:

Is it too late to invest in hemp stocks? No! This is the perfect time to invest.

Wall Street analysts expect the global cannabis industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in hemp stocks is now. 

Are you interested in hemp stocks like GW Pharmaceuticals, Charlotte’s Web, Canopy Growth, or Hemp Inc.?

Are you looking to buy stock in hemp companies or marijuana companies in 2020? Interested in emerging penny hemp stocks? Interested in leveraging the power of algorithmic stock trades to profit from hemp stocks? Looking for the best Canadian cannabis stocks to invest in? We can help.

Predict price movements of hemp stocks several hours in advance with our proprietary algorithmic stock trading software.

  • +25% Gains in 2020
  • +49.8% Gains in 2019
  • Backtested since 2012

At Cannin, we’re so confident you’ll love our algotrading hemp stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.

Profit from the best hemp stocks – we’ll show you how at

Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Best Hemp Stocks